Welcome to our dedicated page for PEAR news (Ticker: PEAR), a resource for investors and traders seeking the latest updates and insights on PEAR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PEAR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PEAR's position in the market.
Pear Therapeutics, Inc. (Nasdaq: PEAR) will release its Q1 2022 financial results on May 16, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss the company’s financial highlights and business developments. The call can be accessed via telephone or through a live webcast on Pear's website. Pear Therapeutics is a leader in developing prescription digital therapeutics (PDTs), focusing on improving patient outcomes and healthcare engagement.
Pear Therapeutics (Nasdaq: PEAR) will host a Vision Session at the Rx and Illicit Drug Summit in Atlanta, GA, from April 18-21. This session, titled "Recovery is in Your Hands: How Access to Digital Therapeutics Can Drive Outcomes", aims to discuss the role of prescription digital therapeutics (PDTs) in treating substance use and opioid use disorders. Chief Medical Officer Yuri Maricich emphasized the need to address health disparities exacerbated by the COVID-19 pandemic. Panelists will include industry leaders exploring how PDTs can enhance care access for underserved populations.
Pear Therapeutics, Inc. (Nasdaq: PEAR) has received Safer Technologies Program (STeP) designation from the FDA for Pear-010, a prescription digital therapeutic aimed at treating acute and chronic pain. This product targets patients 18 and older, intended to reduce pain and the need for opioids after surgery. With over 50 million U.S. patients suffering from pain, Pear-010 could provide an alternative to opioid therapies. The STeP designation aims to expedite development and access to medical devices, although Pear-010 has not yet received marketing authorization.
Pear Therapeutics, Inc. (NASDAQ: PEAR) announced its participation in two virtual investor conferences in April 2022. CEO Corey McCann will speak at the Chardan Prescription Digital Therapeutics Summit on April 11 at 1:00 p.m. ET, while CFO Chris Guiffre will present at the Needham Virtual Healthcare Conference on April 12 at 11:00 a.m. ET. Webcasts will be accessible via Pear's website, with replays available for 30 days post-event. Pear Therapeutics leads in developing software-based medicines known as prescription digital therapeutics (PDTs), aiming to enhance patient care and outcomes.
Pear Therapeutics (NASDAQ: PEAR) has launched a telehealth initiative aimed at aiding patients with substance use disorder (SUD) and opioid use disorder (OUD). The program connects patients to clinicians through Pear's 'find a provider tool' and prioritizes access to FDA-authorized prescription digital therapeutics, including reSET® and reSET-O®. The first partnership is with PursueCare, enabling comprehensive virtual care across 12 states. This approach aims to address the sharp increase in substance abuse during the COVID-19 pandemic and enhance equity of access to treatment.
Pear Therapeutics, Inc. (NASDAQ: PEAR), a leader in prescription digital therapeutics (PDTs), will participate in the Credit Suisse Hidden Gems Conference on April 7 in New York, NY. The company's management will be available for one-on-one meetings with institutional investors. Pear Therapeutics aims to redefine healthcare with clinically validated PDTs, boasting FDA-approved products like reSET® for substance use disorder, reSET-O® for opioid use disorder, and Somryst® for insomnia. For more details, visit www.peartherapeutics.com.
Pear Therapeutics, Inc. (Nasdaq: PEAR) reported a strong financial performance for 2021, with total revenue reaching $4.2 million, a significant increase from $34 thousand in Q4 2020. The company also achieved over 14,000 prescriptions and covered lives exceeding 31.7 million. Key highlights include the introduction of CPT codes for digital therapeutics and the addition of Pear's products to major formularies, marking significant commercial progress. Looking ahead, Pear anticipates $22 million in revenue for 2022 and aims to expand patient access to its products.
Pear Therapeutics (NASDAQ: PEAR) announced the availability of its PearConnect™ platform within the Epic App Orchard Gallery. This integration allows healthcare providers to remotely monitor patients prescribed FDA-authorized prescription digital therapeutics (PDTs) such as reSET® and reSET-O® for substance use and opioid use disorders. The platform aims to enhance patient management and accessibility, facilitating a streamlined workflow for clinicians. Pear's end-to-end platform supports multiple PDTs and is designed for scalable development and commercialization.
Pear Therapeutics (NASDAQ: PEAR) has partnered with SoftBank Corp. to create a Japanese-language digital therapeutic addressing sleep/wake disorders, targeting a significant unmet need in Japan, where 20% of adults experience chronic sleep deprivation. This collaboration aims to leverage Pear's software-based medicines, including Somryst®, the only FDA-authorized prescription digital therapeutic for chronic insomnia in the U.S. The agreement reinforces Pear's international expansion strategy and aligns with SoftBank's digital transformation goals.
Pear Therapeutics (Nasdaq: PEAR) announced significant interim results from studies of its FDA-authorized digital therapeutic, Somryst®, for chronic insomnia. The DREAM study reported a mean insomnia severity index (ISI) reduction from 18.8 to 11.3 after nine weeks, with sustained improvements through six months. Furthermore, 78.7% achieved remission in sleep onset latency. An additional study highlighted that older adults using the tailored version, SHUTi-OASIS, also experienced significant insomnia reductions over 12 months. These findings underscore the growing importance of accessible, remote treatments.
